Higher-Valency Pneumococcal Conjugate Vaccines: An Exploratory Cost-Effectiveness Analysis in U.S. Seniors

INTRODUCTION: Use of the 13-valent pneumococcal conjugate vaccine (PCV13) in non-immunocompromised adults aged ≥65 years is controversial. Higher-valency conjugate vaccines (PCV15 and PCV20) are under development; their potential cost effectiveness in older adults is unknown, particularly when poten...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Prev Med
Main Authors: Smith, Kenneth J., Wateska, Angela R., Nowalk, Mary Patricia, Lin, Chyongchiou J., Harrison, Lee H., Schaffner, William, Zimmerman, Richard K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8221100/
https://ncbi.nlm.nih.gov/pubmed/34148625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.amepre.2021.01.023
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados